Private Advisor Group LLC Has $5.25 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Private Advisor Group LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 45.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,593 shares of the company’s stock after purchasing an additional 8,369 shares during the quarter. Private Advisor Group LLC’s holdings in Zoetis were worth $5,249,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP lifted its stake in Zoetis by 2.5% in the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares in the last quarter. Northern Trust Corp boosted its holdings in Zoetis by 3.3% during the third quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock worth $1,068,804,000 after purchasing an additional 196,771 shares during the last quarter. Royal Bank of Canada grew its position in Zoetis by 3.1% in the third quarter. Royal Bank of Canada now owns 3,026,518 shares of the company’s stock valued at $526,553,000 after purchasing an additional 91,713 shares in the last quarter. Blair William & Co. IL increased its stake in Zoetis by 1.4% in the 3rd quarter. Blair William & Co. IL now owns 2,428,509 shares of the company’s stock valued at $422,512,000 after buying an additional 32,918 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Zoetis by 0.5% during the 3rd quarter. Principal Financial Group Inc. now owns 2,126,090 shares of the company’s stock worth $369,736,000 after buying an additional 10,153 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 2.1 %

Shares of Zoetis stock opened at $164.92 on Thursday. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock has a market cap of $75.25 billion, a PE ratio of 31.78, a PEG ratio of 2.57 and a beta of 0.86. The firm has a 50-day moving average of $167.64 and a 200-day moving average of $178.93. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.31 earnings per share. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.77 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 2,209 shares of company stock worth $371,293 over the last ninety days. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on ZTS shares. The Goldman Sachs Group reduced their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday. Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. HSBC dropped their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Barclays dropped their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $211.75.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.